1-tert-butyl-3-(1-(4-chlorophenyl)-3-methyl-1-oxobutan-2-yl)urea | 1394017-57-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-tert-butyl-3-(1-(4-chlorophenyl)-3-methyl-1-oxobutan-2-yl)urea
• 英文别名: 1-Tert-butyl-3-[1-(4-chlorophenyl)-3-methyl-1-oxobutan-2-yl]urea
• CAS: 1394017-57-2
• 化学式: C₁₆H₂₃ClN₂O₂
• 分子量: 310.824
• InChiKey: OPWGBOAEYGMIKX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-amino-1-(4-chlorophenyl)-3-methylbutan-1-one hydrochloride 、 叔丁基异氰酸酯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 以18%的产率得到1-tert-butyl-3-(1-(4-chlorophenyl)-3-methyl-1-oxobutan-2-yl)urea
  参考文献：
  名称：

  N-1-Alkyl-2-oxo-2-aryl amides as novel antagonists of the TRPA1 receptor

  摘要：

  A series of potent antagonists of the ion channel transient receptor potential A1 (TRPA1) was developed by modifying lead structure 16 that was discovered by high-throughput screening. Based on lead compound 16, a SAR was established, showing a narrow region at the nitro-aromatic R-1 moiety and at the warhead, while the R-2 side had a much wider scope including ureas and carbamates. Compound 16 inhibits Ca2+-activated TRPA1 currents reversibly in whole cell patch clamp experiments, indicating that under in vivo conditions, it does not react covalently, despite its potentially electrophilic ketone. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.07.032

文献信息

• [EN] TRPA1 ANTAGONIST COMPOUNDS<br/>[FR] COMPOSÉS ANTAGONISTES DE TRPA1
  申请人：ACTURUM LIFE SCIENCE AB

  公开号：WO2014184248A3

  公开（公告）日：2014-12-31
• N-1-Alkyl-2-oxo-2-aryl amides as novel antagonists of the TRPA1 receptor
  作者：Karl S.A. Vallin、Karin J. Sterky、Eva Nyman、Jenny Bernström、Rebecka From、Christian Linde、Alexander B.E. Minidis、Andreas Nolting、Katja Närhi、Ellen M. Santangelo、Fernando W. Sehgelmeble、Daniel Sohn、Jennie Strindlund、Dirk Weigelt

  DOI：10.1016/j.bmcl.2012.07.032

  日期：2012.9

  A series of potent antagonists of the ion channel transient receptor potential A1 (TRPA1) was developed by modifying lead structure 16 that was discovered by high-throughput screening. Based on lead compound 16, a SAR was established, showing a narrow region at the nitro-aromatic R-1 moiety and at the warhead, while the R-2 side had a much wider scope including ureas and carbamates. Compound 16 inhibits Ca2+-activated TRPA1 currents reversibly in whole cell patch clamp experiments, indicating that under in vivo conditions, it does not react covalently, despite its potentially electrophilic ketone. (c) 2012 Elsevier Ltd. All rights reserved.